Prime Capital Investment Advisors LLC Sells 3,763 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Prime Capital Investment Advisors LLC lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,666 shares of the biotechnology company’s stock after selling 3,763 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $354,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in SRPT. PNC Financial Services Group Inc. boosted its position in Sarepta Therapeutics by 189.1% during the first quarter. PNC Financial Services Group Inc. now owns 5,784 shares of the biotechnology company’s stock worth $452,000 after purchasing an additional 3,783 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $185,000. MetLife Investment Management LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter valued at approximately $421,000. Great West Life Assurance Co. Can boosted its position in shares of Sarepta Therapeutics by 6.6% in the first quarter. Great West Life Assurance Co. Can now owns 4,541 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 281 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Sarepta Therapeutics by 12.3% in the first quarter. Dimensional Fund Advisors LP now owns 179,294 shares of the biotechnology company’s stock valued at $14,007,000 after acquiring an additional 19,660 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $122.87 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The stock has a fifty day moving average price of $127.46 and a two-hundred day moving average price of $110.56. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $159.89. The firm has a market capitalization of $11.54 billion, a P/E ratio of -20.08 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $396.80 million during the quarter, compared to analyst estimates of $387.18 million. During the same period in the prior year, the company posted ($1.24) earnings per share. The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. BMO Capital Markets assumed coverage on Sarepta Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price objective for the company. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Evercore ISI increased their price objective on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Needham & Company LLC reduced their price objective on Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Finally, Barclays increased their price objective on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $158.38.

Insiders Place Their Bets

In other news, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock worth $2,739,419 over the last three months. 7.40% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.